Literature DB >> 1998012

Relative antigenicity of components of a vascularized limb allograft.

W P Lee1, M J Yaremchuk, Y C Pan, M A Randolph, C M Tan, A J Weiland.   

Abstract

At present, the transplantation of vascularized limb-tissue allografts can be achieved only with generalized host immunosuppression, which results in significant systemic toxicity, thereby precluding their clinical use. A better understanding of the immunogenic mechanisms of these allografts may permit less toxic and thus clinically applicable means of host immunosuppression. In this study, individual vascularized limb tissues (skin, subcutaneous tissue, muscle, bone, and blood vessels) and a whole limb were transplanted microsurgically across a strong histocompatibility barrier in rats. The respective cell-mediated and humoral immune responses generated in the hosts were determined by means of mixed lymphocyte cultures by radioactive 51Cr release assays and compared. No single tissue predominated in the elicited immune response. Rather, the various tissue components interacted with the host immune system in a complex but predictable pattern with differing timing and intensity. Surprisingly, the whole-limb allograft elicited less immune response than did allografts of its individual components. The data presented here also serve as a foundation for further elucidation of the immunogenic mechanisms of vascularized limb-tissue allografts.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998012     DOI: 10.1097/00006534-199103000-00001

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  54 in total

1.  Experimental and clinical experience with small composite tissue allotransplants and cryopreservation techniques.

Authors:  Jean-Claude Guimberteau; Joseph Bakhach; Vincent Casoli
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

2.  Immune responses in transplantation: application to composite tissue allograft.

Authors:  Aleksandra Klimczak; Maria Siemionow
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

3.  Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.

Authors:  Larry D Bozulic; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Semin Plast Surg       Date:  2007-11       Impact factor: 2.314

Review 4.  Face allotransplantation and burns: a review.

Authors:  Anna Arno; J P Barret; Rachael A Harrison; Marc G Jeschke
Journal:  J Burn Care Res       Date:  2012 Sep-Oct       Impact factor: 1.845

Review 5.  Composite tissue transplantation: a rapidly advancing field.

Authors:  K V Ravindra; S Wu; L Bozulic; H Xu; W C Breidenbach; S T Ildstad
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

6.  Vascularized composite allograft tolerance across MHC barriers in a large animal model.

Authors:  D A Leonard; J M Kurtz; C Mallard; A Albritton; R Duran-Struuck; E A Farkash; R Crepeau; A Matar; B M Horner; M A Randolph; D H Sachs; C A Huang; C L Cetrulo
Journal:  Am J Transplant       Date:  2014-01-09       Impact factor: 8.086

7.  Hand allotransplantation.

Authors:  Gerald Brandacher; Vijay S Gorantla; W P Andrew Lee
Journal:  Semin Plast Surg       Date:  2010-02       Impact factor: 2.314

8.  Inhibition of Complement: Tackling of Both Innate and Adaptive Immune Responses to Dampen Rejection.

Authors:  Sriram Ambadapadi
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 9.  Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases.

Authors:  Iurii Koboziev; Yava Jones-Hall; John F Valentine; Cynthia Reinoso Webb; Kathryn L Furr; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

10.  Canine laryngeal transplantation: preliminary studies and a new heterotopic allotransplantation model.

Authors:  J P Anthony; D B Allen; P P Trabulsy; M Mahdavian; S J Mathes
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.